CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-24 | Jovan-Embiricos Morana 10% owner | Option exercise | +104,845 | $4.30 | $451K | 217,352 |
| 2022-06-24 | Jovan-Embiricos Morana 10% owner | Option exercise | +35,529 | $4.30 | $153K | 252,881 |
| 2022-06-24 | Jovan-Embiricos Morana 10% owner | Shares withheld for taxes | −45,078 | $13.39 | $604K | 207,803 |
| 2022-06-24 | Jovan-Embiricos Morana 10% owner | Option exercise · Stock Option (Right to Buy) | −104,845 | 0 | ||
| 2022-06-24 | Jovan-Embiricos Morana 10% owner | Option exercise · Stock Option (Right to Buy) | −35,529 | 0 | ||
| 2022-06-23 | F2 Bioscience I 2017 Ltd 10% owner | Sale | −29,631 | $13.00 | $385K | 537,392 |
| 2022-06-22 | F2 Bioscience I 2017 Ltd 10% owner | Sale | −49,953 | $12.70 | $635K | 567,023 |
| 2022-06-22 | Ebeling Thomas Director | Grant or award · Stock Option (Right to Buy) | +16,475 | 16,475 | ||
| 2022-06-22 | GADICKE ANSBERT Director | Grant or award · Stock Option (Right to Buy) | +16,475 | 16,475 | ||
| 2022-06-22 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +16,475 | 16,475 | ||
| 2022-06-22 | Rosenberg Anthony Director | Grant or award · Stock Option (Right to Buy) | +16,475 | 16,475 | ||
| 2022-06-21 | F2 Bioscience I 2017 Ltd 10% owner | Sale | −22,319 | $12.77 | $285K | 616,976 |
| 2022-06-06 | AHMED NADIM President and CEO | Purchase | +8,090 | $12.40 | $100K | 8,090 |
| 2022-06-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +405,641 | $11.00 | $4.5M | 4,058,854 |
| 2022-06-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +301,009 | $11.00 | $3.3M | 2,992,808 |
| 2022-06-01 | BVF PARTNERS L P/IL 10% owner | Purchase | +44,746 | $11.00 | $492K | 364,161 |
| 2022-05-16 | F2 Vision SCS 10% owner | Sale | −35,158 | $11.23 | $395K | 1,305,873 |
| 2022-05-13 | F2 Vision SCS 10% owner | Sale | −85,319 | $9.96 | $850K | 1,375,220 |
| 2022-05-13 | F2 Vision SCS 10% owner | Sale | −34,189 | $10.48 | $358K | 1,341,031 |
| 2022-05-13 | BVF PARTNERS L P/IL 10% owner | Purchase | +53,598 | $9.14 | $490K | 3,653,213 |
Page 13 of 23 · 446 trades